DOCSLIB.ORG

The Effect of Β-Cell Specific Znt8 Deficiency on Insulin Secretion

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Effect of Β-Cell Specific Znt8 Deficiency on Insulin Secretion The Effect of β-Cell Specific ZnT8 Deficiency on Insulin Secretion Anne Wu A thesis submitted in conformity with the requirements for the degree of Masters of Physiology Graduate Department of Medicine University of Toronto © Copyright by Anne Wu (2020) The Effect of β-Cell Specific ZnT8 Deficiency on Insulin Secretion Anne Wu Master of Science Department of Physiology University of Toronto 2020 Abstract Zinc plays a role in insulin processing, storage, and secretion. Zinc transport processes may be linked to defects in insulin secretion associated with type 2 diabetes (T2D). Indeed, ZnT8, a zinc influx transporter highly expressed in pancreatic β-cells, is associated with T2D risk. Presently, the role ZnT8 plays in diabetes progression and whether altered ZnT8 activity affects T2D risk/treatment is controversial. The effects of ZnT8 knockdown in mouse are modestly to severely deleterious, whereas in humans, ZnT8 loss- of-function haploinsufficiency appears to reduce diabetes risk. A β-cell specific ZnT8 knockout and haploinsufficiency model were developed and examined under normal and metabolically stressed conditions. Mice with reduced ZnT8 did not have significantly impaired glucose homeostasis or β-cell function compared to controls under normal and conditions of acute insulin resistance. Overall, pancreatic β-cell ZnT8 deletion or knockdown did not impair β-cell function, nor was it protective of hyperglycaemia associated with insulin resistance. ii Acknowledgements Thank you to the entire Wheeler lab for supporting me. Thanks to Dr. Alpana Bhatacharjee, Dr. Feihan Dai, Dana Al Rijjal, Jie Xu, Ashley Untereiner, Dr. Mi Lai, Dr. Saifur Khan for their advice and training. They provided great examples of how to conduct research. Importantly, thanks to Dr. Michael B. Wheeler for providing me this opportunity to grow as both a scientist and as a person. I truly appreciate the adaptations taken to accommodate my learning style. I would be remiss not to thank the organizations who helped fund my schooling. Thanks to the Ontario Graduate Scholarship award (from the Estate of Gladys. A Fidlar), the Banting and Best Diabetes Centre Novo Nordisk Studentship, and the CIHR grant held by Dr. Michael B. Wheeler for providing me with the means to pursue diabetes research. A huge thank you to Dr. Jonathan Rocheleau and Dr. Cynthia Luk, my committee members. They provided valuable insight and offered considerations we would have otherwise missed. I’d like to thank my friends who kept me sane through this degree. They provided a great sounding board for me to talk through my confusion and gave me much needed reminders to take breaks to work more effectively. And finally, I’d like to thank the mice whose sacrifices contributed to further diabetic research. iii Table of Contents Abstract ................................................................................................................................................... ii Acknowledgements ............................................................................................................................... iii Awards and Publications ....................................................................................................................... vii List of Tables ........................................................................................................................................ viii List of Figures ......................................................................................................................................... ix Abbreviations .......................................................................................................................................... x Chapter 1: Introduction .......................................................................................................................... 1 1.1 Zinc Homeostasis .......................................................................................................................... 1 1.1.1 Zinc in Diabetes ...................................................................................................................... 1 1.2 Zinc Transporters .......................................................................................................................... 4 1.3 Zinc Transporter 8 (ZnT8) and Diabetes ....................................................................................... 5 1.3.1 GWAS studies of SLC30A8/ZnT8 ............................................................................................ 6 1.3.2 ZnT8 in Mice ........................................................................................................................... 8 1.3.3 ZnT8 Controversy ................................................................................................................. 10 1.3.4 Other functions of ZnT8 ....................................................................................................... 12 1.4 Rationale ..................................................................................................................................... 14 1.4.1 Hypothesis ........................................................................................................................... 14 1.4.2 Objectives ............................................................................................................................ 15 Chapter 2: Methods .............................................................................................................................. 16 2.1 Model Generation ....................................................................................................................... 16 2.1.1 PCR ....................................................................................................................................... 17 2.2 Islet Isolation ............................................................................................................................... 18 2.3 Knockdown Detection ................................................................................................................. 19 2.3.1 qPCR ..................................................................................................................................... 19 iv 2.3.2 Dithizone staining ................................................................................................................ 20 2.4 Validation of S961 ....................................................................................................................... 20 2.4.1 Daily S961 injection .............................................................................................................. 20 2.4.2 Acute S961 Injection Challenge ........................................................................................... 22 2.5 In vivo experiments ..................................................................................................................... 22 2.5.1 Oral Glucose Tolerance Tests............................................................................................... 22 2.5.2 Acute S961 Challenge .......................................................................................................... 22 2.6 Ex Vivo Experiments .................................................................................................................... 23 2.6.1 Glucose Stimulated Insulin Secretion .................................................................................. 23 2.6.2 Total Islet Insulin .................................................................................................................. 23 2.6.3 Insulin Concentration Measurements ................................................................................. 23 2.7 Statistical Analysis ....................................................................................................................... 24 Chapter 3: Results ................................................................................................................................. 25 3.1 Model Confirmation .................................................................................................................... 25 3.1.1 PCR ....................................................................................................................................... 25 3.1.2 qPCR ..................................................................................................................................... 25 3.2.3 Dithizone staining ................................................................................................................ 26 3.2 S961 Validation ........................................................................................................................... 27 3.2.1 Daily S961 Injections ............................................................................................................ 27 3.2.2 Acute S961 Challenge Validation ......................................................................................... 27 3.3 In vivo data .................................................................................................................................. 30 3.3.1 OGTT .................................................................................................................................... 31 3.3.2 S961 ..................................................................................................................................... 31 3.4
Load more

Recommended publications
  • Are Zinc Transporter Type 8 Antibodies a Marker of Autoimmune Thyroiditis in Non-Obese Adults with New-Onset Diabetes?
    A Rogowicz-Frontczak and ZnT8A are associated with ATPO 170:4 651–658 Clinical Study others in diabetes Are zinc transporter type 8 antibodies a marker of autoimmune thyroiditis in non-obese adults with new-onset diabetes? Anita Rogowicz-Frontczak1, Dorota Zozulin´ ska-Zio´ łkiewicz1, Monika Litwinowicz2, Paweł Niedz´wiecki1, Krystyna Wyka3 and Bogna Wierusz-Wysocka1 Correspondence should be addressed to Departments of 1Internal Medicine and Diabetology and 2Internal Diseases, Metabolic Disorders and Dietetics, A Rogowicz-Frontczak Poznan University of Medical Sciences, Mickiewicza 2, 60-834 Poznan, Poland and 3Medical University of Lodz, Email Lodz, Poland [email protected] Abstract Objective: The diagnosis of autoimmune diabetes in non-obese adults is based on the detection of glutamic acid decarboxylase autoantibodies (GADA), islet cell antibodies (ICA) and antibodies to tyrosine phosphatase (IA-2A). Zinc transporter 8 (ZnT8) has been identified as a new autoantigen in patients with type 1 diabetes mellitus. The coincidence of autoimmune thyroiditis (AITD) with diabetes is common; therefore, screening of TSH and thyroid peroxidase antibodies (ATPO) is recommended during the diagnosis of diabetes. In this study, we determined whether the occurrence of islet autoantibodies is associated with a positive titre of ATPO in newly diagnosed adult-onset autoimmune diabetic patients. Design and methods: The study involved 80 non-obese adults aged 44 (interquartile range (IQR): 37–51) years with a BMI of 24.0 (IQR: 22.2–26.0) kg/m2 and new-onset diabetes. The markers of autoimmune diabetes (GADA, ICA, IA-2A and ZnT8A), TSH and thyroid peroxidase antibodies (ATPO) were evaluated. Results: In the study population, 70% (nZ56) of the subjects were positive for at least one of the four assessed markers of autoimmune diabetes (83.9% GADA, 62.5% ICA, 42.8% IA-2A and 33% ZnT8A) and 37.5% of the subjects were positive for ATPO.
    [Show full text]
  • A Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    Diabetologia https://doi.org/10.1007/s00125-020-05181-w CONSENSUS REPORT Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Wendy K. Chung1,2 & Karel Erion3 & Jose C. Florez4,5,6,7,8 & Andrew T. Hattersley9 & Marie-France Hivert5,10 & Christine G. Lee11 & Mark I. McCarthy12,13,14 & John J. Nolan15 & Jill M. Norris16 & Ewan R. Pearson17 & Louis Philipson 18,19 & Allison T. McElvaine20 & William T. Cefalu11 & Stephen S. Rich21,22 & Paul W. Franks23,24 # European Association for the Study of Diabetes and American Diabetes Association 2020 Abstract The convergence of advances in medical science, human biology, data science and technology has enabled the generation of new insights into the phenotype known as ‘diabetes’. Increased knowledge of this condition has emerged from popu- lations around the world, illuminating the differences in how diabetes presents, its variable prevalence and how best practice in treatment varies between populations. In parallel, focus has been placed on the development of tools for the application of precision medicine to numerous conditions. This Consensus Report presents the American Diabetes Association (ADA) Precision Medicine in Diabetes Initiative in partnership with the European Association for the Study of Diabetes (EASD), including its mission, the current state of the field and prospects for the future. Expert opinions are presented on areas of precision diagnostics and precision therapeutics (including prevention and treatment) and key barriers to and opportunities for implementation of precision diabetes medicine, with better care and outcomes around the globe, are highlighted. Cases where precision diagnosis is already feasible and effective (i.e.
    [Show full text]
  • Mestrado Thais Cristine
    UNIVERSIDADE DE SÃO PAULO FACULDADE DE MEDICINA DE RIBEIRÃO PRETO PROGRAMA DE PÓS-GRADUAÇÃO EM IMUNOLOGIA BÁSICA E APLICADA THAIS CRISTINE ARNS Identificação de cascatas gênicas com base na modulação transcricional de células sanguíneas mononucleares periféricas de pacientes com diabetes mellitus do tipo 1 RIBEIRÃO PRETO 2013 THAIS CRISTINE ARNS Identificação de cascatas gênicas com base na modulação transcricional de células sanguíneas mononucleares periféricas de pacientes com diabetes mellitus do tipo 1 Dissertação apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo para obtenção do título de Mestre em Ciências. Área de Concentração: Imunologia Orientador: Prof. Dr. Geraldo Aleixo da Silva Passos Júnior RIBEIRÃO PRETO 2013 AUTORIZO A REPRODUÇÃO E DIVULGAÇÃO TOTAL OU PARCIAL DESTE TRABALHO, POR QUALQUER MEIO CONVENCIONAL OU ELETRÔNICO, PARA FINS DE ESTUDO E PESQUISA, DESDE QUE CITADA A FONTE. FICHA CATALOGRÁFICA Arns, Thais Cristine Identificação de cascatas gênicas com base na modulação transcricional de células sanguíneas mononucleares periféricas de pacientes com diabetes mellitus do tipo 1. Ribeirão Preto, 2013. 159p. Dissertação de Mestrado apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo. Área de concentração: Imunologia. Orientador: Passos, Geraldo Aleixo 1. Diabetes do tipo 1, 2. Microarrays, 3. Gene Set Analysis (GSA), 4. Expressão gênica, 5. Bioinformática. FOLHA DE APROVAÇÃO THAIS CRISTINE ARNS Identificação de cascatas gênicas com base na modulação transcricional de células sanguíneas mononucleares periféricas de pacientes com diabetes mellitus do tipo 1 Dissertação apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo para obtenção do título de Mestre em Ciências. Área de Concentração: Imunologia Aprovado em: __________________ Banca Examinadora Prof.
    [Show full text]
  • Análise Integrativa De Perfis Transcricionais De Pacientes Com
    UNIVERSIDADE DE SÃO PAULO FACULDADE DE MEDICINA DE RIBEIRÃO PRETO PROGRAMA DE PÓS-GRADUAÇÃO EM GENÉTICA ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Ribeirão Preto – 2012 ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Tese apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo para obtenção do título de Doutor em Ciências. Área de Concentração: Genética Orientador: Prof. Dr. Eduardo Antonio Donadi Co-orientador: Prof. Dr. Geraldo A. S. Passos Ribeirão Preto – 2012 AUTORIZO A REPRODUÇÃO E DIVULGAÇÃO TOTAL OU PARCIAL DESTE TRABALHO, POR QUALQUER MEIO CONVENCIONAL OU ELETRÔNICO, PARA FINS DE ESTUDO E PESQUISA, DESDE QUE CITADA A FONTE. FICHA CATALOGRÁFICA Evangelista, Adriane Feijó Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas. Ribeirão Preto, 2012 192p. Tese de Doutorado apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo. Área de Concentração: Genética. Orientador: Donadi, Eduardo Antonio Co-orientador: Passos, Geraldo A. 1. Expressão gênica – microarrays 2. Análise bioinformática por module maps 3. Diabetes mellitus tipo 1 4. Diabetes mellitus tipo 2 5. Diabetes mellitus gestacional FOLHA DE APROVAÇÃO ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas.
    [Show full text]
  • Genetics of Type 2 Diabetes: Insights Into the Pathogenesis and Its Clinical Application
    Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 926713, 15 pages http://dx.doi.org/10.1155/2014/926713 Review Article Genetics of Type 2 Diabetes: Insights into the Pathogenesis and Its Clinical Application Xue Sun,1 Weihui Yu,2 and Cheng Hu1,3 1 Shanghai Diabetes Institute, Shanghai Clinical Center for Diabetes, Shanghai Key Clinical Center for Metabolic Disease, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China 2 Department of Endocrinology and Metabolism, Wenzhou Medical University Affiliated First Hospital, Wenzhou 325000, China 3 Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, South Branch, Shanghai 200233, China Correspondence should be addressed to Cheng Hu; [email protected] Received 7 March 2014; Accepted 22 March 2014; Published 17 April 2014 Academic Editor: Jiarui Wu Copyright © 2014 Xue Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. With rapidly increasing prevalence, diabetes has become one of the major causes of mortality worldwide. According to the latest studies, genetic information makes substantial contributions towards the prediction of diabetes risk and individualized antidiabetic treatment. To date, approximately 70 susceptibility genes have been identified as being associated with type 2 diabetes (T2D) ata −8 genome-wide significant level (<5×10 ). However, all the genetic loci identified so far account for only about 10% of the overall heritability of T2D. In addition, how these novel susceptibility loci correlate with the pathophysiology of the disease remains largely unknown.
    [Show full text]
  • Targeting the Zinc Transporter ZIP7 in the Treatment of Insulin Resistance and Type 2 Diabetes
    nutrients Review Targeting the Zinc Transporter ZIP7 in the Treatment of Insulin Resistance and Type 2 Diabetes John Adulcikas, Sabrina Sonda, Shaghayegh Norouzi, Sukhwinder Singh Sohal and Stephen Myers * College of Health and Medicine, School of Health Sciences, University of Tasmania, TAS 7005, Australia; [email protected] (J.A.); [email protected] (S.S.); [email protected] (S.N.); [email protected] (S.S.S.) * Correspondence: [email protected]; Tel.: +61-3-6324-5459 Received: 20 December 2018; Accepted: 12 February 2019; Published: 15 February 2019 Abstract: Type 2 diabetes mellitus (T2DM) is a disease associated with dysfunctional metabolic processes that lead to abnormally high levels of blood glucose. Preceding the development of T2DM is insulin resistance (IR), a disorder associated with suppressed or delayed responses to insulin. The effects of this response are predominately mediated through aberrant cell signalling processes and compromised glucose uptake into peripheral tissue including adipose, liver and skeletal muscle. Moreover, a major factor considered to be the cause of IR is endoplasmic reticulum (ER) stress. This subcellular organelle plays a pivotal role in protein folding and processes that increase ER stress, leads to maladaptive responses that result in cell death. Recently, zinc and the proteins that transport this metal ion have been implicated in the ER stress response. Specifically, the ER-specific zinc transporter ZIP7, coined the “gate-keeper” of zinc release from the ER into the cytosol, was shown to be essential for maintaining ER homeostasis in intestinal epithelium and myeloid leukaemia cells. Moreover, ZIP7 controls essential cell signalling pathways similar to insulin and activates glucose uptake in skeletal muscle.
    [Show full text]
  • The Effect of Acid on the Dynamics of Intracellular Zinc and the Marker Expressions Of
    The Effect of Acid on the Dynamics of Intracellular Zinc and the Marker Expressions of Pluripotency in Somatic Cells A thesis presented to the faculty of the College of Arts and Sciences of Ohio University In partial fulfillment of the requirements for the degree Master of Science Yuli Hu April 2021 © 2021 Yuli Hu. All Rights Reserved. 2 This thesis titled The Effect of Acid on the Dynamics of Intracellular Zinc and the Marker Expressions of Pluripotency in Somatic Cells by YULI HU has been approved for the Department of Biological Sciences and the College of Arts and Sciences by Yang V. Li Professor of Biomedical Sciences Florenz Plassmann Dean, College of Arts and Sciences 3 Abstract YULI HU, M.S., April 2021, Biological Sciences The Effect of Acid on the Dynamics of Intracellular Zinc and the Marker Expressions of Pluripotency in Somatic Cells Director of Thesis: Yang V. Li Microenvironmental pH is one of the factors that affect the stability of zinc- protein binding. The tight binding between zinc and proteins is favored by the basic pH, whereas acidic pH favors a loose bound, and treatment of strong acid results in the dissociation of zinc. Physiologically, the stomach uses a very acidic pH to digest food which results in a high amount of soluble zinc in the stomach. Whether or not zinc co- present with acid and the effect of zinc on the gastric lining has rarely been discussed. In my experiments, acidic treatment induced the expression of a pluripotent marker in primary cultured gastric cells. It also stimulated the release of intracellular zinc, suggesting that acidic pH supported protein expression through dynamic zinc regulation.
    [Show full text]
  • Transporters
    Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators (2019). The Concise Guide to Pharmacology 2019/20: Transporters. British Journal of Pharmacology, 176(S1), S397-S493. https://doi.org/10.1111/bph.14753 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.14753 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.14753. Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters Stephen PH Alexander1 , Eamonn Kelly2, Alistair Mathie3 ,JohnAPeters4 , Emma L Veale3 , Jane F Armstrong5 , Elena Faccenda5 ,SimonDHarding5 ,AdamJPawson5 , Joanna L Sharman5 , Christopher Southan5 , Jamie A Davies5 and CGTP Collaborators 1School of Life Sciences,
    [Show full text]
  • New Mesh Headings for 2018 Single Column After Cutover
    New MeSH Headings for 2018 Listed in alphabetical order with Heading, Scope Note, Annotation (AN), and Tree Locations 2-Hydroxypropyl-beta-cyclodextrin Derivative of beta-cyclodextrin that is used as an excipient for steroid drugs and as a lipid chelator. Tree locations: beta-Cyclodextrins D04.345.103.333.500 D09.301.915.400.375.333.500 D09.698.365.855.400.375.333.500 AAA Domain An approximately 250 amino acid domain common to AAA ATPases and AAA Proteins. It consists of a highly conserved N-terminal P-Loop ATPase subdomain with an alpha-beta-alpha conformation, and a less-conserved C- terminal subdomain with an all alpha conformation. The N-terminal subdomain includes Walker A and Walker B motifs which function in ATP binding and hydrolysis. Tree locations: Amino Acid Motifs G02.111.570.820.709.275.500.913 AAA Proteins A large, highly conserved and functionally diverse superfamily of NTPases and nucleotide-binding proteins that are characterized by a conserved 200 to 250 amino acid nucleotide-binding and catalytic domain, the AAA+ module. They assemble into hexameric ring complexes that function in the energy-dependent remodeling of macromolecules. Members include ATPASES ASSOCIATED WITH DIVERSE CELLULAR ACTIVITIES. Tree locations: Acid Anhydride Hydrolases D08.811.277.040.013 Carrier Proteins D12.776.157.025 Abuse-Deterrent Formulations Drug formulations or delivery systems intended to discourage the abuse of CONTROLLED SUBSTANCES. These may include physical barriers to prevent chewing or crushing the drug; chemical barriers that prevent extraction of psychoactive ingredients; agonist-antagonist combinations to reduce euphoria associated with abuse; aversion, where controlled substances are combined with others that will produce an unpleasant effect if the patient manipulates the dosage form or exceeds the recommended dose; delivery systems that are resistant to abuse such as implants; or combinations of these methods.
    [Show full text]
  • Supplemental Data
    Article TCF7L2 is a master regulator of insulin production and processing ZHOU, Yuedan, et al. Abstract Genome-wide association studies have revealed >60 loci associated with type 2 diabetes (T2D), but the underlying causal variants and functional mechanisms remain largely elusive. Although variants in TCF7L2 confer the strongest risk of T2D among common variants by presumed effects on islet function, the molecular mechanisms are not yet well understood. Using RNA-sequencing, we have identified a TCF7L2-regulated transcriptional network responsible for its effect on insulin secretion in rodent and human pancreatic islets. ISL1 is a primary target of TCF7L2 and regulates proinsulin production and processing via MAFA, PDX1, NKX6.1, PCSK1, PCSK2 and SLC30A8, thereby providing evidence for a coordinated regulation of insulin production and processing. The risk T-allele of rs7903146 was associated with increased TCF7L2 expression, and decreased insulin content and secretion. Using gene expression profiles of 66 human pancreatic islets donors', we also show that the identified TCF7L2-ISL1 transcriptional network is regulated in a genotype-dependent manner. Taken together, these results demonstrate that not only synthesis of [...] Reference ZHOU, Yuedan, et al. TCF7L2 is a master regulator of insulin production and processing. Human Molecular Genetics, 2014, vol. 23, no. 24, p. 6419-6431 DOI : 10.1093/hmg/ddu359 PMID : 25015099 Available at: http://archive-ouverte.unige.ch/unige:45177 Disclaimer: layout of this document may differ from the published
    [Show full text]
  • Insulin Crystallization Depends on Zinc Transporter Znt8 Expression, but Is Not Required for Normal Glucose Homeostasis in Mice
    Insulin crystallization depends on zinc transporter ZnT8 expression, but is not required for normal glucose homeostasis in mice K. Lemairea,1, M. A. Ravierb,c,1, A. Schraenena, J. W. M. Creemersd, R. Van de Plase, M. Granvika, L. Van Lommela, E. Waelkensf, F. Chimientig, G. A. Rutterh, P. Gilonb, P. A. in’t Veldi, and F. C. Schuita,2 aGene Expression Unit, Department Molecular Cell Biology, Katholieke Universiteit Leuven, Herestraat 49, 3000 Leuven, Belgium; bUnit of Endocrinology and Metabolism, University of Louvain, Faculty of Medicine, Université Catholique de Louvain 55.30, 1200 Brussels, Belgium; cInstitut National de la Sante´et de la Recherche Me´dicale, U661, Equipe avenir, Centre National de la Recherche Scientifique, Unite´Mixte de Recherche 5203, Universite´Montpellier (IFR3), Institut de Ge´nomique Fonctionnelle, 34090 Montpellier, France; dDepartment of Human Genetics, Katholieke Universiteit Leuven, Herestraat 49, 3000 Leuven, Belgium; eDepartment of Electrical Engineering, Katholieke Universiteit Leuven, Kasteelpark Arenberg 10, 3001 Leuven, Belgium; fPrometa, Department of Molecular Cell Biology, Katholieke Universiteit Leuven, Herestraat 49, 3000 Leuven, Belgium; gMellitech, SAS, Commissariat a` l’E´ nergie Atomique, 17 rue des Martyrs, 38054 Grenoble, France; hDepartment of Cell Biology Division of Medicine Sir Alexander Fleming Building Imperial College, London Exhibition Road, London SW7 2AZ, United Kingdom; and iDepartment of Pathology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium Edited by Donald F. Steiner, University of Chicago, Chicago, IL and approved July 16, 2009 (received for review June 15, 2009) Zinc co-crystallizes with insulin in dense core secretory granules, extracellular space as well as transport of zinc from the cytosol but its role in insulin biosynthesis, storage and secretion is un- into intracellular organelles is mediated by 10 known isoforms of known.
    [Show full text]
  • Genetic Basis of Metabolic Evolution in the Cave Fish Astyanax Mexicanus
    Genetic Basis of Metabolic Evolution in the Cave Fish Astyanax Mexicanus The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:40050145 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Gene�c Basis of Metabolic Evolu�on in the Cave fish Astyanax mexicanus A disserta�on presented by Ariel Cacayuran Aspiras to The Division of Medical Sciences in par�al fulfillment of the requirements for the degree of Doctor of Philosophy in the subject of Biological and Biomedical Sciences Harvard University Cambridge, Massachuse�s May 2018 ©2018 by Ariel Cacayuran Aspiras All rights reserved. iii Dissertation Advisor: Dr. Clifford Tabin Ariel Cacayuran Aspiras Genetic Basis of Metabolic Evolution in the Cave fish Astyanax mexicanus Abstract Organisms evolve to thrive in new environments. In spite of the role metabolism plays in adaptation, the genetic basis for metabolic variation remains poorly understood. Here we use independently derived populations of Astyanax mexicanus, a Mexican tetra, to interrogate the genetic basis of extreme metabolic variation between surface and cave adapted populations. In the cave environment, food is much more scarce than in nutrient-rich rivers. Cave populations of Astyanax mexicanus rely on sporadic input of food from outside the cave. As a result, cave fish populations have evolved a suite of metabolic traits such as: starvation resistance, hyperphagia, hyperglycemia, and insulin resistance.
    [Show full text]